Axios Re:Cap

Latest Episodes:

Nasdaq exec on proposed diversity rules for listed companies Dec 01, 2020

Show notes

The Nasdaq today said it will ask federal securities regulators to approve new rules that would require its listed companies to regularly report on the demographic diversity of their boards, and also comply with board diversity requirements. Dan goes deeper with Jeff Thomas, Nasdaq's senior VP of corporate services, to learn why Nasdaq is enacting this policy, the internal discussions that led to it and what happens to companies that don't comply.

Former Georgia Gov. Roy Barnes on the Senate runoffs Nov 30, 2020

Show notes

The future of U.S. politics, and all that flows from it, is in the hands of Georgia voters when they cast their votes in two Senate runoffs on Jan. 5. Dan digs into the election dynamics with former Georgia Gov. Roy Barnes, a Democrat who served from 1999 to 2003.

Walmart U.S. CEO on Thanksgiving grocery and Black Friday shopping trends Nov 25, 2020

Show notes

Amazon may get more media buzz, but there is simply no retailer, or grocer, in America that does more business than does Walmart. And that gives John Furner, its head of U.S. operations, one of the best views into Black Friday and Thanksgiving grocery shopping. Dan talks to Furner about what he's seeing from his unique perch, and what pandemic-driven changes he expects will outlast the virus.

Butterball CEO Jay Jandrain talks turkey Nov 24, 2020

Show notes

Butterball estimates that it sells one out of every three Thanksgiving turkeys, but knows that this year's celebrations will be a lot different than in years past. Dan talks with the turkey giant's CEO Jay Jandrain about what people are buying, what they're asking the "Turkey Talkline" and what the pandemic has meant for his business.

Biotech investor Bob Nelsen on AstraZeneca and his plan to revolutionize pharma Nov 23, 2020

Show notes

AstraZeneca and the University of Oxford today reported promising efficacy data for their COVID-19 vaccine, which has less stringent storage requirements than the Pfizer and Moderna vaccines and which may be distributed earlier in developing countries. Dan digs into the state of vaccine and therapeutics manufacturing with Bob Nelsen, a successful biotech investor who today launched Resilience, a giant new pharma production platform that he believes will prepare America for its next major health challenges.

Plus, Axios health care editor Sam Baker joins to discuss AstraZeneca’s interim analysis.

The future of air travel Nov 21, 2020

Show notes

U.S. air travel is down 65%, but lots of people are expected to fly this week, in defiance of CDC guidelines.

Axios Re:Cap digs into the future of air travel, America’s largest plane maker and concerns over what this week could mean. Our guests are Axios reporters Joann Muller, Courtenay Brown and Erica Pandey.

Black Friday 2020 and the future of retail Nov 19, 2020

Show notes

We're eight days away from Black Friday, but this year it might be about a lot more than bargains or doorbuster stampedes. Instead, it could help determine if certain retailers will survive past 2020, or at least if they hold on to physical stores. Dan talks with Fortune senior reporter Phil Wahba about which retailers have the most to gain or lose next week and the broader future of retail.

Joe Biden's plan to forgive student debt Nov 18, 2020

Show notes

President-elect Biden this week endorsed a proposal to immediately forgive up to $10,000 in student debt, with some experts arguing that he could do so via executive action. Dan speaks with Mike Pierce, policy director for the Student Borrower Protection Center, about Biden's plan, why it matters and what comes next.

Skift CEO Rafat Ali on Airbnb's IPO and the future of travel Nov 18, 2020

Show notes

Airbnb filed for its IPO yesterday, and showed some glimmers of hope for a travel and hospitality industry that has been hit particularly hard by the pandemic. Dan speaks with Skift co-founder and CEO Rafat Ali about what he learned from Airbnb's IPO prospectus, lessons for hoteliers and what will be left once COVID-19 is contained.

Moderna's chief medical officer on its blockbuster vaccine news Nov 16, 2020

Show notes

Moderna Therapeutics today reported a 94.5% efficacy for its COVID-19 vaccine, which needn't be stored at the same ultra-cold temperatures as does a similar vaccine developed by Pfizer. It also said short-term safety concerns, such as headaches and injection site soreness, self-resolved within days, and that it could have 20 million doses available by year-end. Dan speaks with Moderna chief medical officer Tal Zaks about the new data, distribution, politics, and how it was preparing for this moment even before COVID-19 was discovered.

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected